Any current/future new fundraising through debt or equity?

UTI Alternatives subsidiary is in the process of closing SDOF-I and SDOF-II funds, expected to be fully closed soon. Existing funds currently in fund-raising mode within UTI Alternatives will be entering their financial close shortly. No explicit mention of new or future fundraising through equity; focus is on debt-related fund closures and new product launches in alternatives. Emphasis on launching appropriate new products across all business lines, including alternatives, indicating potential future fundraising initiatives. No direct reference to equity capital raising in the discussion.

Any current/future capex/capital investment/strategic investment?

UTI AMC and its subsidiaries are investing in expanding their geographical presence including opening new offices in New York, USA, and Paris, France, as well as enhancing the Middle East operations by upgrading regulatory licenses in DIFC. Significant investments are being made in hiring and upskilling human capital across geographies such as the USA, France, Singapore, Dubai, and within India to support future business growth. There is a focus on digital resource augmentation, including partnerships like with Salesforce, revisiting digital assets, and strengthening risk management processes

Future growth expectations in sales/revenue/volumes?

Focus on absolute profit growth rather than yield, as yield margins may decline due to asset mix and inflows, but overall profit will increase with volume growth (Imtaiyazur Rahman). PAT margin expected to improve due to operating leverage and volume growth, despite declining yield margins (Vinay Lakhotia). Significant improvement in SIP inflows driven by fintech, banks, distributors, and better fund performance; strong inflows expected to sustain (Sandeep Samsi). Alternative business anticipated to become core PAT positive from next financial year, adding to overall profitability (Vinay Lakho

Future growth expectations in earnings/operating earnings/profits/EPS?

Focus on absolute profit growth rather than yield, with overall profit expected to rise despite yield pressure (Imtaiyazur Rahman, Page 16). PAT margin expected to improve due to operating leverage and volume growth, although yield margins may decline due to asset mix and fresh inflows (Vinay Lakhotia, Page 16). UTI Alternative expected to turn core PAT positive from the beginning of next financial year, adding to standalone profits (Vinay Lakhotia, Page 14). Overall consolidated PAT for H1 FY25 increased 18% YoY to ₹493 crore; standalone PAT up 29% YoY for H1 FY25 (Page 6). Employee cost incr

UTI AMCQ2 FY25Capital Markets

UTI AMC Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹824.55P/E: 19.9Market Cap: ₹10.6K CrSector: Capital Markets

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Focus on absolute profit growth rather than yield, as yield margins may decline due to asset mix and inflows, but overall profit will increase with volume growth (Imtaiyazur Rahman).
PAT margin expected to improve due to operating leverage and volume growth, despite declining yield margins (Vinay Lakhotia).
Significant improvement in SIP inflows driven by fintech, banks, distributors, and better fund performance; strong inflows expected to sustain (Sandeep Samsi).
Alternative business anticipated to become core PAT positive from next financial year, adding to overall profitability (Vinay Lakhotia).
Expansion internationally (offices in Paris, USA, Singapore, Dubai) and investments in subsidiaries expected to drive growth (Vinay Lakhotia, Imtaiyazur Rahman).
Market share gains targeted through improved fund performance, distribution, and product positioning (Imtaiyazur Rahman).
Overall growth supported by strong industry trends and rising investor participation, especially in SIP and ETFs.

Margin guidance

Category 3

Focus on absolute profit growth rather than yield, with overall profit expected to rise despite yield pressure (Imtaiyazur Rahman, Page 16).
PAT margin expected to improve due to operating leverage and volume growth, although yield margins may decline due to asset mix and fresh inflows (Vinay Lakhotia, Page 16).
UTI Alternative expected to turn core PAT positive from the beginning of next financial year, adding to standalone profits (Vinay Lakhotia, Page 14).
Overall consolidated PAT for H1 FY25 increased 18% YoY to ₹493 crore; standalone PAT up 29% YoY for H1 FY25 (Page 6).
Employee cost increase guided at 2%-3% standalone and ~4% consolidated, with cost efficiencies expected from lean sales model and retirements (Page 12).
Digital and geographic expansions to support future growth, balanced by controlled cost increases (Pages 11-12).
Better fund performances and improved market share expected to drive sustainable growth in assets under management and profits.

See what UTI AMC management said on margin guidance — free account, 30 seconds.

Fundraise plans

UTI Alternatives subsidiary is in the process of closing SDOF-I and SDOF-II funds, expected to be fully closed soon.
Existing funds currently in fund-raising mode within UTI Alternatives will be entering their financial close shortly.
No explicit mention of new or future fundraising through equity; focus is on debt-related fund closures and new product launches in alternatives.
Emphasis on launching appropriate new products across all business lines, including alternatives, indicating potential future fundraising initiatives.
No direct reference to equity capital raising in the discussion.

Order book

The provided pages from the UTI Asset Management Company Limited Q2 & H1 FY25 Earnings Conference Call transcript do not mention any details related to a current or expected orderbook or pending orders. The discussion primarily focuses on: - Fund performance, SIP inflows, and AUM growth. - Revenue yields and profitability metrics. - Employee costs and branch expansions. - Market share, product strategy, and business segment outlook. - Subsidiaries' performance and future expectations. - Commission rationalization and cost management. No information on orderbook or pending orders is available in the provided text.

See what UTI AMC management said on order book — free account, 30 seconds.

Capex plans

Yes

UTI AMC and its subsidiaries are investing in expanding their geographical presence including opening new offices in New York, USA, and Paris, France, as well as enhancing the Middle East operations by upgrading regulatory licenses in DIFC.
Significant investments are being made in hiring and upskilling human capital across geographies such as the USA, France, Singapore, Dubai, and within India to support future business growth.
There is a focus on digital resource augmentation, including partnerships like with Salesforce, revisiting digital assets, and strengthening risk management processes globally.
UTI Pension Fund Limited is building a strong sales and distribution network with 16 branch offices across Bharat to increase private sector market share.
The company is launching new products across business lines and investing in brand building, product distribution, and operation upgrades for medium-to-long-term growth.
Initial establishment and rental costs of international offices (Paris and USA) have contributed to increased expenses but are strategic investments for future growth.

Track UTI AMC — get its next earnings analysis in your feed

How does UTI AMC rank vs peers in Capital Markets?

Pro feature

ThisUTI AMC

Rev 3Mar 3

See where UTI AMC sits in Capital MarketsSee which companies these are, and every other name in the sector.Open rankings

How does UTI AMC rank in Capital Markets?

Compare UTI AMC against every Capital Markets company (Q2 FY25) on revenue, margins and earnings-call signals.

View Capital Markets leaderboard →

What UTI AMC's management said in earlier quarters

Others in Capital Markets this season

Pune e-Stock Broking Ltd (Q1 FY27)
For H2 FY26, Revenue from Operations was ₹27.5 Crore, up 20.4% YoY from ₹22.8 Crore in H2 FY25. Key investor presentation takeaways from Pune e-Stock Broking Lt
CARE Ratings (Q2 FY27)
164.13 Crs, up 20% YoY (Page 2) . Key investor presentation takeaways from CARE Ratings Ltd's Q2 FY27 investor presentation — and how it ranks against sector pe
Computer Age Management Services Ltd (Q2 FY27)
Q2 FY’27 Revenue from operations: ₹41,446.57 Lakh, up 10.0% YoY (₹37,673.79 Lakh in Q2 FY’26). Key investor presentation takeaways from Computer Age Management
ICRA (Q2 FY27)
Q2 FY2027 Group Revenue: ₹177.9 crore (up from ₹136.6 crore in Q2 FY2026) – ~30.2% YoY growth . Key investor presentation takeaways from ICRA Ltd's Q2 FY27 inve

Compare:vs National Stock Exchange Of India Ltd vs BSE vs ICICI AMC

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

UTI AMC Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does UTI AMC rank in Capital Markets?

Continue your research

What UTI AMC's management said in earlier quarters

Others in Capital Markets this season